Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12419690 | 0.87 | HDAC1 (0.50) | ALDH1A1PKMSCDSMN1; SMN2 | |
| SCHEMBL2192142 | 0.83 | DRD2 (0.43) | DRD2DRD3KCNH2ALDH1A1KMT2A | |
| SCHEMBL2194058 | 0.79 | KMT2A (0.41) | DRD2DRD3KCNH2ALDH1A1KMT2A | |
| SCHEMBL23019862 | 0.76 | LCK (0.40) | DRD2DRD3KCNH2 | |
| SCHEMBL12419689 | 0.75 | HDAC1 (0.52) | ALDH1A1PKMSCDSMN1; SMN2 | |
| SCHEMBL2192398 | 0.72 | CRHR1 (0.51) | GPR52 | |
| SCHEMBL19402116 | 0.70 | IDH1 (0.47) | — | |
| SCHEMBL12419692 | 0.69 | HDAC1 (0.50) | ALDH1A1PKMSCDSMN1; SMN2 | |
| SCHEMBL22241436 | 0.69 | ROCK2 (0.43) | DRD2DRD3ALDH1A1PKMGPR52 | |
| SCHEMBL2191407 | 0.69 | KMT2A (0.56) | ALDH1A1KMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | DRD2 264/4885DRD3 316/4885KCNH2 2993/4885 |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR2, NR3C2, CRHR1 | DRD2 193/4885DRD3 171/4885KCNH2 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.